Recommendation of the President – Tecentriq (atezolizumab)

On 23 July 2024, the President of the Agency for Health Technology Assessment and Tariff System issued  recommendation No. 77/2024 on the inclusion of the medicinal product Tecentriq (atezolizumab) in the reimbursement within the framework of the therapeutic programme ‘Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)’

Publication in Public Information Bulletin (BIP) >>